Table 2.
The patient medication information is displayed by type of antipsychotic, number of patients and chlorpromazine equivalents. The chlorpromazine equivalents had trend level significance between typical and atypical groups (p = 0.07).
| Typicals | Patients (n) | Chlorpromazine Equivalents (mg) mean (SD) |
|---|---|---|
| Haloperidol | 3 | 433.33 (57.74) |
| Haloperidol decanoate | 1 | 1175 |
| Fluphenazine | 1 | 500 |
| Fluphenazine decanoate | 1 | 1350 |
| Thiothixene | 1 | 667 |
| Totals | 7 | 713 (389.02) |
| Atypicals | ||
| Clozapine | 10 | 880 (404.97) |
| Aripiprazole | 12 | 283.33 (180.07) |
| Olanzapine | 7 | 675 (232.29) |
| Quetiapine | 11 | 486.36 (317.88) |
| Risperidone | 18 | 169.44 (96.85) |
| Risperidone consta | 4 | 225 (104.08) |
| Ziprasidone | 5 | 157.5 (100.62) |
| Combination atypical* | 5 | 930 (516.72) |
| Totals | 72 | 439.76 (516.72) |
*
The combination atypical antipsychotics included the following five combinations: aripiprazole and quetiapine, aripiprazole and risperidone consta, aripiprazole and olanzapine, clozapine and quetiapine, clozapine and olanzapine. Patients were excluded from the analysis if they were on combination typical and atypical antipsychotics.